INGR changes
Pick any two versions below to diff them.
- Price
- $97.27 → $95.68(−1.6%)
- Discount
- 24% to 44% → 25% to 45%(+1.0 pts)
- Next earnings
- 2026-11-04 → 2026-11-05
- Next earnings is estimate
- Yes → No
- Thesis
- The market doubts the earnings power of Ingredion's base business and fears the cost of the Tate & Lyle purchase. Operational problems at the Argo plant, after a thermal event, cut Food & Industrial Ingredients U.S./CAN operating income by 48% in the first half of 2026, and Ingredion cut its 2026 adjusted EPS guidance to $10.30 to $10.90. Demand for sweeteners and starches in the US and Mexico is also soft. At the same time, Ingredion will pay 595 pence per share in cash for Tate & Lyle, an enterprise value of about £3.7 billion, at a premium of about 59% to the price before the offer. It will fund the deal with new debt, and it expects net leverage of about 3.0 times at completion, against debt of $1.8 billion at June 30, 2026. Investors ask whether the price is too high and whether the antitrust review will delay or change the deal. For the gap to close, four things must be true. Argo must stay at normal production rates, so that U.S./CAN operating income recovers in 2027. Texture & Healthful Solutions must keep its volume growth, which reached nine quarters in a row in Q2 2026. The Tate & Lyle deal must pass its antitrust conditions and close in the second half of 2027, as planned. After closing, Ingredion must deliver the planned net cost synergies of about $130 million a year by the end of 2030 and reduce leverage to about 2.5 times within about 18 months. The Q3 2026 report, expected in early on November 5, 2026, gives the first evidence on Argo, and the antitrust decisions and the deal closing in 2027 give the rest. If these checks pass, the gap can close over the next four to eight quarters.
- Checkpoints
- Nov 45, 2026 (estimate): Q3 2026 results: Argo recovery and guidance. Pending. Watch: U.S./CAN operating income that improves with Argo at normal rates and the 2026 adjusted EPS guidance of $10.30 to $10.90 kept pass; another guidance cut fails. Feb 2027 (estimate): Full-year 2026 results and 2027 outlook. Pending. Watch: A 2027 outlook with higher operating income in U.S./CAN and continued volume growth in Texture & Healthful Solutions passes; a lower 2027 outlook fails. Q4 2027 (estimate): Tate & Lyle antitrust approvals and completion. Pending. Watch: Completion in the second half of 2027 without large required sales of businesses passes; a delay past early 2028 or a blocked deal fails.